Schering's reports disappointing diagnostic results:
This article was originally published in Clinica
Executive Summary
Schering's diagnostic sales fell by 6% to DM1,480 million ($865 million) in 1998, despite increased volume sales. Sales of X-ray contrast media were DM1,084 million, down 5%. This was largely due to government-imposed price cuts in Japan and the weakness of Asian currencies, the German company says. Pricing pressures caused by strong competition led to a 9% fall in sales of MRI contrast media to DM387 million. The Berlin-based company says its echo enhancement agent for ultrasound diagnosis, Levovist, "has still not recorded significant sales".
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.